• SPX
  • $5,983.08
  • -0.04 %
  • -$2.30
  • DJI
  • $43,902.06
  • -0.13 %
  • -$56.13
  • N225
  • $38,535.70
  • -0.48 %
  • -$185.96
  • FTSE
  • $8,066.42
  • 0.45 %
  • $36.09
  • IXIC
  • $19,215.39
  • -0.08 %
  • -$15.35
Capricor Therapeutics, Inc. (CAPR) Stock Price, News & Analysis

Capricor Therapeutics, Inc. (CAPR) Stock Price, News & Analysis

Currency in USD Disclaimer

$17.66

$0.75

(4.44%)

Day's range
$16.92
Day's range
$18.76
50-day range
$3.98
Day's range
$23.4
  • Country: US
  • ISIN: US14070B3096
52 wk range
$2.87
Day's range
$23.4
  • CEO: Dr. Linda Marbán Ph.D.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 9.02
  • Piotroski Score 2.00
  • Grade Buy
  • Symbol (CAPR)
  • Company Capricor Therapeutics, Inc.
  • Price $17.66
  • Changes Percentage (4.44%)
  • Change $0.75
  • Day Low $16.92
  • Day High $18.76
  • Year High $23.40

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 11/13/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $37.50
  • High Stock Price Target $43.00
  • Low Stock Price Target $25.00
  • Potential Upside/Downside N/A
  • Consensus Rating Strong Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$0.83
  • Trailing P/E Ratio -6.31
  • Forward P/E Ratio -6.31
  • P/E Growth -6.31
  • Net Income $-22,287,542

Income Statement

Quarterly

Annual

Latest News of CAPR

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.